V181

BIOLOGICAL2 trials

Sponsors

Butantan Institute, Merck Sharp & Dohme LLC

Conditions

DengueHealthy

Phase 2

Clinical Bridging Study Between V181 (Dengue Quadrivalent Vaccine rDENVΔ30 [Live, Attenuated]) to Butantan Dengue Vaccine (Butantan - DV) in Healthy Adults 18 to 50 Years of Age in Brazil (V181 - 002)

CompletedNCT05710224

Butantan InstituteDengue

Start: 2023-02-15End: 2024-12-12Updated: 2025-11-18

Phase 3

A Study to Evaluate V181 Dengue Vaccine in Healthy Participants 2 to 17 Years of Age (V181-005/MOBILIZE-1)

RecruitingNCT07013487

Merck Sharp & Dohme LLCHealthy

Start: 2025-06-11End: 2031-10-24Target: 12000Updated: 2026-09-10

Related Papers

Safety and Immunogenicity of the Live-Attenuated Quadrivalent Dengue Vaccine V181 Compared With Butantan-DV Among Healthy Adults in Brazil: A Randomized, Double-Blind, Phase 2 Trial.

PubMed2026-07-01

Therapeutic Approaches Against Dengue Virus: Current Status of Vaccines, Antivirals, and Monoclonal Antibodies.

2026-06-08